文献速递流行病学与生物统计临床试验与 GCP

HIV合并耐多药结核成人抗逆转录病毒治疗与结核药物使用对死亡率的影响:个体患者数据荟萃分析

Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis.
PubMed 文献 · Lancet · 2020-01-01

HIV阳性者中使用至少一种WHO A组药物及莫西沙星、左氧氟沙星、贝达喹啉或利奈唑胺与死亡 odds 显著降低相关。

要点

  • 使用至少一种WHO A组药物或莫西沙星、左氧氟沙星、贝达喹啉、利奈唑胺与死亡 odds 降低相关。

核心结论

  • HIV阳性耐多药结核患者使用ART及更有效的抗结核药物与较低的死亡 odds 相关。
  • 应紧急推动这些治疗的可及性。

研究设计与样本

  • 个体患者数据荟萃分析,纳入1993—2016年启动结核治疗的18岁及以上确诊或疑似耐多药结核成人。
  • 主要分析比较HIV阳性与HIV阴性患者治疗期间死亡,排除失访者,并按ART使用分层;采用国家世界银行收入分类和耐药性的精确匹配及年龄、性别、地理站点、耐多药结核治疗启动年份、既往结核治疗、直接面视下治疗和抗酸杆菌涂片阳性的倾向评分匹配后行logistic回归。

主要发现

  • HIV阳性患者中,使用至少一种WHO A组药物及特定使用莫西沙星、左氧氟沙星、贝达喹啉或利奈唑胺与死亡 odds 显著降低相关。

临床怎么用

  • 对HIV合并耐多药结核成人应使用ART以降低死亡风险。
  • 抗结核方案中应优先包含至少一种WHO A组药物,如莫西沙星、左氧氟沙星、贝达喹啉或利奈唑胺。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HIV-infection is associated with increased mortality during multidrug-resistant tuberculosis treatment, but the extent to which the use of antiretroviral therapy (ART) and anti-tuberculosis medications modify this risk are unclear. Our objective was to evaluate how use of these treatments altered mortality risk in HIV-positive adults with multidrug-resistant tuberculosis. METHODS: We did an individual patient data meta-analysis of adults 18 years or older with confirmed or presumed multidrug-resistant tuberculosis initiating tuberculosis treatment between 1993 and 2016. Data included ART use and anti-tuberculosis medications grouped according to WHO effectiveness categories. The primary analysis compared HIV-positive with HIV-negative patients in terms of death during multidrug-resistant tuberculosis treatment, excluding those lost to follow up, and was stratified by ART use. Analyses used logistic regression after exact matching on country World Bank income classification and drug resistance and propensity-score matching on age, sex, geographic site, year of multidrug-resistant tuberculosis treatment initiation, previous tuberculosis treatment, directly observed therapy, and acid-fast-bacilli smear-positivity to obtain adjusted odds ratios (aORs) and 95% CIs. Secondary analyses were conducted among those with HIV-infection. FINDINGS: We included 11 920 multidrug-resistant tuberculosis patients. 2997 (25%) were HIV-positive and on ART, 886 (7%) were HIV-positive and not on ART, and 1749 (15%) had extensively drug-resistant tuberculosis. By use of HIV-negative patients as reference, the aOR of death was 2·4 (95% CI 2·0-2·9) for all patients with HIV-infection, 1·8 (1·5-2·2) for HIV-positive patients on ART, and 4·2 (3·0-5·9) for HIV-positive patients with no or unknown ART. Among patients with HIV, use of at least one WHO Group A drug and specific use of moxifloxacin, levofloxacin, bedaquiline, or linezolid were associated with significantly decreased odds of death. INTERPRETATION: Use of ART and more effective anti-tuberculosis drugs is associated with lower odds of death among HIV-positive patients with multidrug-resistant tuberculosis. Access to these therapies should be urgently pursued. FUNDING: American Thoracic Society, Canadian Institutes of Health Research, US Centers for Disease Control and Prevention, European Respiratory Society, Infectious Diseases Society of America.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Bisson GP, Bastos M, Campbell JR, et al. Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. Lancet. 2020. PMID: 32771107. doi:10.1016/S0140-6736(20)31316-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。